This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Efficacy and tolerability of Ginkgo biloba extract EGb 761 by type of dementia: analyses of a randomised controlled trial


Napryeyenko, Oleksandr, Sonnik, Grigoriy, Tartakovsky, Igor


Journal Of The Neurological Sciences, Volume: 283, No.: 1-2, Pages.: 224-229

Year of Publication



Secondary analyses of a randomised controlled trial were performed to find out whether treatment effects of Ginkgo biloba extract EGb 761 differed by type of dementia. Three hundred ninety-five patients aged 50 years or above, with dementia with neuropsychiatric features were treated with EGb 761 (240 mg/day) or placebo for 22 weeks. Patients scored between 9 and 23 on the Short Syndrome Test (SKT), a cross-culturally validated cognitive test battery. Their total score on the Neuropsychiatric Inventory (NPI) was at least 5. Efficacy was assessed by the SKT test battery (primary outcome measure), the Verbal Fluency Test, the Clock-Drawing Test, the NPI, the Hamilton Rating Scale for Depression (HAMD), and the Gottfries-Bråne-Steen Scale (GBS). Applying standard research diagnostic criteria 214 patients were diagnosed with Alzheimer’s disease (probable AD or possible AD with cerebrovascular disease) and 181 with probable vascular dementia (VaD). Under EGb 761 treatment the SKT total score improved by -3.0+/-2.3 and -3.4+/-2.3 points in patients with AD and VaD, respectively, whereas the patients on placebo deteriorated by +1.2+/-2.5 and +1.5+/-2.2 points, respectively (p<0.01 for both drug-placebo differences). Significant drug-placebo differences were found for all secondary outcome variables with no major differences between AD and VaD subgroups. The rate of adverse events tended to be higher for the placebo group.;

Bibtex Citation

@article{Napryeyenko_2009, doi = {10.1016/j.jns.2009.02.353}, url = {}, year = 2009, month = {aug}, publisher = {Elsevier {BV}}, volume = {283}, number = {1-2}, pages = {224--229}, author = {Oleksandr Napryeyenko and Grigoriy Sonnik and Igor Tartakovsky}, title = {Efficacy and tolerability of Ginkgo biloba extract {EGb} 761{textregistered} by type of dementia: Analyses of a randomised controlled trial}, journal = {Journal of the Neurological Sciences} }


adverse effects, aged, alzheimer disease, biloba, cardiovascular agents, dementia vascular, drug therapy, female, ginko, humans, male, neuropsychological tests, plant extracts, psychiatric status rating scales, therapeutic use, treatment outcome

Countries of Study


Types of Dementia

Dementia (general / unspecified)

Types of Study

Randomised Controlled Trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Herbal remedies, vitamins, dietary supplements